Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Lambda and Lonafarnib for Chronic Delta Hepatitis
NCT05953545Phase 2Withdrawn
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon lambda-1a, lonafarnib in hepatitis D (HDV), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Planned start May 2024; status: withdrawn.
02
Drugs
peginterferon lambda-1alonafarnib
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT05953545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953545.